Encorafenib

Drug Profile

Encorafenib

Alternative Names: LGX-818; NVP-LGX818; NVP-LGX818-NXA

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Array BioPharma; German Cancer Research Center; Novartis Pharmaceuticals Corporation; University of Heidelberg
  • Class Antineoplastics; Carbamates; Pyrazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Colorectal cancer; Malignant melanoma
  • Phase II Multiple myeloma; Solid tumours

Most Recent Events

  • 14 Nov 2016 9203218 - Added backdated HE for Special Protocol Assessment, which had been missed
  • 10 Nov 2016 Novartis terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Spain, Germany, Canada, Australia, USA due to scientific and business considerations (PO) (NCT01820364)
  • 09 Nov 2016 Positive topline efficacy and adverse events data from the phase III COLUMBUS trial in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) released by Array BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top